They need a good analyst on the topic/company for sure, or better yet a pharma deal around one or more of these GPCRs.
Press release wasn't bad, and I'm sure Omeros looked at what they could say without facing potential legal issues, but it failed (in my mind) to really elucidate what this could mean for the Company.